D. E. Shaw & Co., Inc. Regeneron Pharmaceuticals, Inc. Transaction History

D. E. Shaw & Co., Inc.

$114 Billion
Q1 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 230,471 shares of REGN stock, worth $226 Million. This represents 0.2% of its overall portfolio holdings.

Number of Shares

230,471

Previous 7,500 2972.95%

Holding current value

$226 Million

Previous $6.59 Million 3267.63%

% of portfolio

0.2%

Previous 0.01%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$902.69 - $993.35 $121 Million - $133 Million	-133,587 Reduced 36.69%	230,471 $222 Million
Q4 2023 Feb 14, 2024	SELL	$775.18 - $881.7 $4.93 Million - $5.61 Million	-6,363 Reduced 1.72%	364,058 $320 Million
Q3 2023 Nov 14, 2023	BUY	$692.45 - $844.37 $57.2 Million - $69.8 Million	82,642 Added 28.72%	370,421 $305 Million
Q2 2023 Aug 14, 2023	BUY	$700.03 - $830.35 $95.5 Million - $113 Million	136,446 Added 90.16%	287,779 $207 Million
Q1 2023 May 15, 2023	BUY	$680.49 - $826.97 $91.9 Million - $112 Million	135,038 Added 828.71%	151,333 $124 Million

Q4 2022 Feb 14, 2023	SELL	$705.89 - $766.39 $14.9 Million - $16.2 Million	-21,130 Reduced 56.46%	16,295 $11.8 Million
Q3 2022 Nov 14, 2022	SELL	$573.97 - $724.32 $15.4 Million - $19.5 Million	-26,903 Reduced 41.82%	37,425 $25.8 Million
Q2 2022 Aug 15, 2022	SELL	$548.35 - $738.84 $74.2 Million - $100 Million	-135,375 Reduced 67.79%	64,328 $38 Million
Q1 2022 May 16, 2022	SELL	$595.12 - $698.43 $55.4 Million - $65.1 Million	-93,168 Reduced 31.81%	199,703 $139 Million
Q4 2021 Feb 14, 2022	BUY	$543.48 - $670.97 $65.6 Million - $81 Million	120,736 Added 70.14%	292,871 $185 Million
Q3 2021 Nov 15, 2021	BUY	$574.03 - $680.96 $68.4 Million - $81.1 Million	119,119 Added 224.69%	172,135 $104 Million
Q2 2021 Aug 16, 2021	BUY	$472.8 - $558.54 $15.3 Million - $18 Million	32,316 Added 156.12%	53,016 $29.6 Million
Q1 2021 May 17, 2021	SELL	$446.73 - $548.2 $15.6 Million - $19.2 Million	-34,958 Reduced 62.81%	20,700 $9.79 Million
Q4 2020 Feb 16, 2021	BUY	$478.3 - $607.98 $3.58 Million - $4.56 Million	7,495 Added 15.56%	55,658 $26.9 Million
Q3 2020 Nov 16, 2020	BUY	$544.75 - $658.21 $7.66 Million - $9.25 Million	14,060 Added 41.23%	48,163 $27 Million
Q2 2020 Aug 14, 2020	SELL	$493.32 - $643.92 $2.21 Million - $2.89 Million	-4,485 Reduced 11.62%	34,103 $21.3 Million
Q1 2020 May 15, 2020	SELL	$336.18 - $494.43 $14.1 Million - $20.7 Million	-41,893 Reduced 52.05%	38,588 $18.8 Million
Q4 2019 Feb 14, 2020	SELL	$274.13 - $376.51 $15.4 Million - $21.2 Million	-56,341 Reduced 41.18%	80,481 $30.2 Million
Q3 2019 Nov 14, 2019	SELL	$273.46 - $318.39 $31.2 Million - $36.4 Million	-114,237 Reduced 45.5%	136,822 $38 Million
Q2 2019 Aug 14, 2019	BUY	$299.6 - $414.82 $18.8 Million - $26 Million	62,639 Added 33.24%	251,059 $78.6 Million
Q1 2019 May 15, 2019	SELL	$372.08 - $439.57 $63.3 Million - $74.8 Million	-170,246 Reduced 47.47%	188,420 $77.4 Million
Q4 2018 Feb 14, 2019	BUY	$335.82 - $403.04 $52.7 Million - $63.3 Million	156,989 Added 77.84%	358,666 $134 Million
Q3 2018 Nov 14, 2018	SELL	$351.14 - $408.51 $43.2 Million - $50.2 Million	-122,963 Reduced 37.88%	201,677 $81.5 Million
Q2 2018 Aug 14, 2018	SELL	$284.6 - $344.99 $94.8 Million - $115 Million	-333,070 Reduced 50.64%	324,640 $112 Million
Q1 2018 May 15, 2018	BUY	$315.82 - $393.78 $38.5 Million - $48 Million	122,000 Added 22.77%	657,710 $226 Million
Q4 2017 Feb 14, 2018	BUY	$358.63 - $469.95 $160 Million - $210 Million	446,025 Added 497.32%	535,710 $201 Million
Q3 2017 Nov 14, 2017	BUY	$431.38 - $504.0 $38.7 Million - $45.2 Million	89,685	89,685 $40.1 Million

Others Institutions Holding REGN

# of Institutions

1,426

Shares Held

82.1M

Call Options Held

835K

Put Options Held

1.46M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $105B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account